Nothing Special   »   [go: up one dir, main page]

EA202091786A1 - Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс - Google Patents

Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс

Info

Publication number
EA202091786A1
EA202091786A1 EA202091786A EA202091786A EA202091786A1 EA 202091786 A1 EA202091786 A1 EA 202091786A1 EA 202091786 A EA202091786 A EA 202091786A EA 202091786 A EA202091786 A EA 202091786A EA 202091786 A1 EA202091786 A1 EA 202091786A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vegf
compositions
treatment
methods
angiogenic disorders
Prior art date
Application number
EA202091786A
Other languages
English (en)
Inventor
Наполеоне ФЕРРАРА
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Publication of EA202091786A1 publication Critical patent/EA202091786A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложены способы и композиции для лечения ангиогенных расстройств с применением агентов против ФРЭС. Агенты против ФРЭС содержат ФРЭС-связывающие домены и обладают способностью связывать стекловидное тело. Предложены иллюстративные варианты осуществления слитых белков Fc-IgG с ФРЭС-связывающими доменами с сильными характеристиками связывания гепарина, сильным ингибированием митогенной активности ФРЭС и улучшенной фармакокинетикой, а именно более длительными периодами полувыведения агентов против ФРЭС и, следовательно, менее частым введением доз.
EA202091786A 2018-01-26 2019-01-25 Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс EA202091786A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622382P 2018-01-26 2018-01-26
PCT/US2019/015160 WO2019147944A1 (en) 2018-01-26 2019-01-25 Methods and compositions for treatment of angiogenic disordres using anti-vegf agents

Publications (1)

Publication Number Publication Date
EA202091786A1 true EA202091786A1 (ru) 2020-10-20

Family

ID=67395742

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091786A EA202091786A1 (ru) 2018-01-26 2019-01-25 Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс

Country Status (14)

Country Link
US (2) US11524053B2 (ru)
EP (1) EP3743091B1 (ru)
JP (2) JP7517988B2 (ru)
KR (1) KR20200112893A (ru)
CN (2) CN111741761B (ru)
AU (2) AU2019212622B2 (ru)
BR (1) BR112020015074A2 (ru)
CA (1) CA3089481A1 (ru)
CO (1) CO2020010384A2 (ru)
EA (1) EA202091786A1 (ru)
IL (2) IL276158B2 (ru)
MX (1) MX2021001424A (ru)
SG (1) SG11202007130RA (ru)
WO (1) WO2019147944A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途
CN117304307A (zh) * 2022-06-27 2023-12-29 上海鼎新基因科技有限公司 一种治疗新生血管相关眼底疾病的aav药物

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
DK0694042T3 (da) 1993-03-25 2005-02-14 Merck & Co Inc Inhibitor af vaskulær endothelcellevækstfaktor
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3011144B2 (ja) 1997-07-31 2000-02-21 日本電気株式会社 光スキャナとその駆動方法
MEP3208A (xx) * 1999-06-08 2010-02-10 Regeneron Pharma Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
ATE375141T1 (de) 2000-03-10 2007-10-15 Insite Vision Inc Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
JP2006527198A (ja) 2003-06-06 2006-11-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆインヒビターを用いる腫瘍退縮方法
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CA2545187A1 (en) 2003-11-10 2005-05-26 Greenville Hospital System Vegf receptor antagonists
AU2005254058A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for the treatment of human cancer
MX2007004374A (es) 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
US7354581B2 (en) 2005-02-11 2008-04-08 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist and anti-hypertensive agent
NZ560879A (en) 2005-02-18 2010-04-30 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
LT2586459T (lt) 2005-03-25 2017-09-25 Regeneron Pharmaceuticals, Inc. Vegf antagonisto kompozicijos
US7531172B2 (en) 2005-08-12 2009-05-12 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a VEGF antagonist
JP2009505989A (ja) 2005-08-15 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＶＥＧＦによって活性化されるＦａｓリガンド
CN100471872C (zh) 2005-11-04 2009-03-25 余波 包含vegf受体片段的优化融合蛋白质及其医疗应用
ES2400666T5 (es) 2005-12-16 2016-03-10 Regeneron Pharmaceuticals, Inc. Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
BRPI0709338A2 (pt) 2006-03-21 2011-07-12 Genentech Inc anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
PL2364691T3 (pl) 2006-06-16 2013-08-30 Regeneron Pharma Formulacje antagonistów VEGF odpowiednie do podawania śródszklistkowego
DK2099489T3 (da) 2006-12-11 2014-08-18 Genentech Inc Sammensætninger og fremgangsmåder til behandling af en neoplasme
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
KR20120022699A (ko) * 2008-12-11 2012-03-12 한국과학기술원 Vegf-a 및 tnf-알파에 결합할 수 있는 융합 단백질
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
KR101248912B1 (ko) * 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
EP2601214B1 (en) 2010-08-06 2017-11-01 Genzyme Corporation Vegf antagonist compositions and uses thereof
KR20140043313A (ko) 2011-01-13 2014-04-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
AU2013207778B2 (en) 2012-01-13 2017-10-12 Genentech, Inc. Biological markers for identifying patients for treatment with VEGF antagonists
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
KR20150083117A (ko) 2012-11-08 2015-07-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
DK2968461T3 (da) 2013-03-13 2022-12-19 Genzyme Corp Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
WO2015038669A1 (en) 2013-09-11 2015-03-19 Neurotech Usa, Inc. Encapsulated cell therapy cartridge
UA117045C2 (uk) 2014-01-25 2018-06-11 Ченгду Кангхонг Байотекнолоджиз Ко., Лтд. Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
KR101844596B1 (ko) 2014-03-18 2018-04-05 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질을 포함하는 안질환 치료용 조성물
WO2015173260A1 (en) 2014-05-12 2015-11-19 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
AU2015318207B2 (en) 2014-09-16 2021-11-04 Regeneron Pharmaceuticals, Inc. Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
EP3581184B1 (en) 2014-11-07 2021-02-24 AI Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
EP3280360B1 (en) 2015-04-07 2022-04-06 Zimmer, Inc. Convertible glenoid
KR20180012832A (ko) 2015-06-28 2018-02-06 올제네시스 바이오테라퓨틱스 아이엔씨. 혈관신생 억제용 융합 단백질
US20180326126A1 (en) 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
EP3412288A1 (en) 2017-06-08 2018-12-12 Galderma Research & Development Vegf inhibitors for use for preventing and/or treating acne
CN111032092A (zh) 2017-06-30 2020-04-17 韩国科学技术院 Vegf-grab蛋白与药物的缀合物及其用途
MA50174A (fr) 2017-09-18 2020-07-29 Amgen Inc Formules de protéines de fusion vegfr-fc
CN109575140B (zh) 2017-09-29 2021-02-23 北京比洋生物技术有限公司 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
CA3082899A1 (en) 2017-11-17 2019-05-23 Amgen Inc. Vegfr-fc fusion protein formulations
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular

Also Published As

Publication number Publication date
KR20200112893A (ko) 2020-10-05
IL276158A (en) 2020-09-30
US20240366721A1 (en) 2024-11-07
AU2019212622A1 (en) 2020-08-13
EP3743091A4 (en) 2021-12-15
WO2019147944A1 (en) 2019-08-01
SG11202007130RA (en) 2020-08-28
JP2024149493A (ja) 2024-10-18
IL310376A (en) 2024-03-01
EP3743091A1 (en) 2020-12-02
CN111741761B (zh) 2023-04-18
AU2024204947A1 (en) 2024-08-08
AU2019212622B2 (en) 2024-05-23
IL276158B1 (en) 2024-03-01
BR112020015074A2 (pt) 2020-12-08
MX2021001424A (es) 2021-06-23
CN111741761A (zh) 2020-10-02
WO2019147944A8 (en) 2020-08-20
CN116059318A (zh) 2023-05-05
CA3089481A1 (en) 2019-08-01
CO2020010384A2 (es) 2020-12-10
JP2021511061A (ja) 2021-05-06
US20200353041A1 (en) 2020-11-12
JP7517988B2 (ja) 2024-07-17
US11524053B2 (en) 2022-12-13
EP3743091B1 (en) 2024-11-06
IL276158B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
EA202091786A1 (ru) Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
EA201890143A3 (ru) Антитела против pdgfr-бета и их применения
EA201792522A1 (ru) Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4
EA201791984A1 (ru) Способы уменьшения уровня fc-содержащих агентов в сыворотке с применением fcrn-антагонистов
EA201891909A1 (ru) TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
MX2020009152A (es) Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
EA202091410A1 (ru) Применение антагонистов fcrn для лечения генерализованной миастении гравис
EA201990747A1 (ru) Способы лечения иммунных нарушений с применением белков, связывающих pd–1
MY190209A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
EA202191892A1 (ru) Ингибиторы pcsk9 и способы их применения
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
JP2016116527A5 (ru)
EA202092420A1 (ru) Антитело против pd-l1 и его применение
CO2022008204A2 (es) Anticuerpos biparatópicos frente a cd73
NZ741780A (en) Anti-htra1 antibodies and methods of use thereof
EA202092162A1 (ru) Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака
MX2022005850A (es) Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
EA201990822A1 (ru) Иммуномодулирующие слитые белки
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA202191430A1 (ru) Производные бис-октагидрофенантренкарбоксамида и их белковые конъюгаты
MX2022006881A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.